Novo Nordisk A/S Ár/értékesítés
Mi az Novo Nordisk A/S Ár/értékesítés?
A Ár/értékesítés az Novo Nordisk A/S - 13.34
Mi a Ár/értékesítés meghatározása?
Az ár / árbevétel arány a vállalat részvényeinek árbevételéhez képest.
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Ár/értékesítés a Miscellaneous szektor a LSE-on cégekben a Novo Nordisk A/S -hoz képest
Mit csinál Novo Nordisk A/S?
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
ár/értékesítés -hoz hasonló cégek Novo Nordisk A/S
- Futu Ltd nak Ár/értékesítés 13.30 van
- Tianfeng Securities Co nak Ár/értékesítés 13.30 van
- SpringWorks Therapeutics nak Ár/értékesítés 13.31 van
- Kronos Bio nak Ár/értékesítés 13.33 van
- Bogota Corp nak Ár/értékesítés 13.33 van
- Azelio AB (publ) nak Ár/értékesítés 13.34 van
- Novo Nordisk A/S nak Ár/értékesítés 13.34 van
- 333D nak Ár/értékesítés 13.34 van
- CK Infrastructure nak Ár/értékesítés 13.35 van
- Bombardier nak Ár/értékesítés 13.36 van
- First Trust-abrdn Emerging Opportunity Fund nak Ár/értékesítés 13.37 van
- BlackRock MuniYield Quality Fund III Inc nak Ár/értékesítés 13.37 van
- Softimat S.A nak Ár/értékesítés 13.37 van